Group 1 - The core point of the article is that Kangyuan Pharmaceutical (600557) has received a supplementary data notification from the National Medical Products Administration regarding Longqi Capsules, indicating that the company will need to supplement relevant experimental research [1] Group 2 - The company responded to investor inquiries on September 10 through an interactive platform [1] - The notification requires the company to conduct additional research trials as part of the approval process [1]